# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

н		
	OMB Number:	3235-0287
l	Estimated average but	rden
l	hours per response:	0.5

(City)	(State)	(Zip)	—	Person			
(Street) CAMBRIDGE	MA	02139	4. If Amendment, Date of Original Filed (Month/Day/Year)		d by One Reportir d by More than O	ng Person	e
(Last) (First) (Middle) C/O MAGENTA THERAPEUTICS, INC. 100 TECHNOLOGY SQUARE			3. Date of Earliest Transaction (Month/Day/Year) 09/16/2021	Ch	ief People Offi	below)	
1. Name and Addre	•	g Person <sup>*</sup>	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Magenta Therapeutics, Inc.</u> [ MGTA ]	5. Relationship of (Check all applica Director	ble)	n(s) to Issuer 10% Owner Other (specify	
to Section 16. From obligations may Instruction 1(b).	orm 4 or Form 5 continue. See		Filed pursuant to Section 16(a) of the Securities Exchange Act of 193 or Section 30(h) of the Investment Company Act of 1940	34	Estimated avera hours per respor	0	.5

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Disposed Of 5)			Securities Beneficially	(D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price			
Common Stock	09/16/2021		<b>S</b> <sup>(1)</sup>		5,736	D	<b>\$6.73</b> <sup>(2)</sup>	14,264	D	

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned         (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		nd 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

### Explanation of Responses:

1. This transaction represents shares sold solely to pay taxes due upon the vesting of restricted stock units, as disclosed by the reporting person on the Form 4 filed on September 16, 2021.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$6.60 to \$6.87, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

#### **Remarks:**

### /s/ Cindy Driscoll, Attorneyin-Fact for Kristen Stants

\*\* Signature of Reporting Person Date

09/20/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject